LC-MS/MS determination of ginsenoside compound K and its metabolite 20 (S)-protopanaxadiol in human plasma and urine : applications in a clinical study
AIM: Ginsenoside compound K (CK) is considered to be a potential therapeutic drug for rheumatoid arthritis because of its good anti-inflammatory activity. The purpose of this work was to establish a rapid, sensitive and specific method for determination of CK and its active metabolite 20(S)-protopanaxadiol (20(S)-PPD). Materials & methods: The analytes and internal standards were extracted by liquid-liquid extraction. Then, were separated by high performance liquid phase and determined by triple quadrupole mass spectrometry.
RESULTS: A LC-MS/MS using liquid-liquid extraction was developed for determining CK over the concentration range 1.00-1002.00 ng/ml and 0.15-54.30 ng/ml for 20(S)-PPD. The lower limits of quantification for CK and 20(S)-PPD were 1.00 and 0.15 ng/ml, respectively.
CONCLUSION: This method was successfully validated for detecting both CK and 20(S)-PPD in the human plasma and urine, and was proved to be suitable for the pharmacokinetic study of CK in healthy Chinese volunteers.
CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-TRC-14004824.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Bioanalysis - 11(2019), 5 vom: 26. März, Seite 365-380 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Li [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
20()-protopanaxadiol |
|---|
| Anmerkungen: |
Date Completed 26.07.2019 Date Revised 26.07.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2018-0185 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM294969217 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM294969217 | ||
| 003 | DE-627 | ||
| 005 | 20231225082636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2018-0185 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0983.xml |
| 035 | |a (DE-627)NLM294969217 | ||
| 035 | |a (NLM)30873858 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a LC-MS/MS determination of ginsenoside compound K and its metabolite 20 (S)-protopanaxadiol in human plasma and urine |b applications in a clinical study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2019 | ||
| 500 | |a Date Revised 26.07.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: Ginsenoside compound K (CK) is considered to be a potential therapeutic drug for rheumatoid arthritis because of its good anti-inflammatory activity. The purpose of this work was to establish a rapid, sensitive and specific method for determination of CK and its active metabolite 20(S)-protopanaxadiol (20(S)-PPD). Materials & methods: The analytes and internal standards were extracted by liquid-liquid extraction. Then, were separated by high performance liquid phase and determined by triple quadrupole mass spectrometry | ||
| 520 | |a RESULTS: A LC-MS/MS using liquid-liquid extraction was developed for determining CK over the concentration range 1.00-1002.00 ng/ml and 0.15-54.30 ng/ml for 20(S)-PPD. The lower limits of quantification for CK and 20(S)-PPD were 1.00 and 0.15 ng/ml, respectively | ||
| 520 | |a CONCLUSION: This method was successfully validated for detecting both CK and 20(S)-PPD in the human plasma and urine, and was proved to be suitable for the pharmacokinetic study of CK in healthy Chinese volunteers | ||
| 520 | |a CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR-TRC-14004824 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 20()-protopanaxadiol | |
| 650 | 4 | |a LC–MS/MS | |
| 650 | 4 | |a ginsenoside compound K | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 7 | |a Ginsenosides |2 NLM | |
| 650 | 7 | |a Sapogenins |2 NLM | |
| 650 | 7 | |a ginsenoside M1 |2 NLM | |
| 650 | 7 | |a A9RLM212CY |2 NLM | |
| 650 | 7 | |a protopanaxadiol |2 NLM | |
| 650 | 7 | |a P6717R7BP8 |2 NLM | |
| 700 | 1 | |a Wang, Chun-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xiao-Nv |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yi-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Jing-Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wei-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Ouyang, Dong-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Zhi-Rong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 11(2019), 5 vom: 26. März, Seite 365-380 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:5 |g day:26 |g month:03 |g pages:365-380 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2018-0185 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 5 |b 26 |c 03 |h 365-380 | ||